20.08.2012 - German chemicals company BASF, US-based Cargill and Danish biotech
Novozymes join forces to develop technologies to produce acrylic acid from
renewable feed stocks.
BASF SE, the world's largest producer of acrylic acid, will join the research collaboration with Novozymes A/S and Cargill Inc., which have already worked together on renewable acrylic technology since 2008. Both firms have been involved in the development of microorganisms that are capable of producing 3-hydroxypropionic acid (3-HP) from renewable feedstock. 3-HP is one potential chemical precursor for the synthesis of acrylic acid.
The bio-based acrylic acid will first be used to manufacture superabsorbent polymers, which can soak up large amounts of liquid and are used mainly in baby diapers and other hygiene products, but also in adhesive raw materials and coatings.
According to the three companies, the annual global market volume of acrylic acid was approximately 4.5 million tons with a value of around US-$11bn at the end of 2011, with a annual growth rate of about 4%.
24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.
23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.
17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.
12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.
10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.
05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.